



HYPMED



intrasense®

Press  
Release

Montpellier (France), February 14 ,2018 – 05:45 pm CET

## Intrasense partner of the Hypmed project, highlighted in ECR

Intrasense (FR0011179886 - ALINS), specialist in medical imaging software solutions, announces that the Hypmed project, in which it is a partner, will be presented at ECR (*European Congress of Radiology* – 25.000 participants), in a special session in Vienna (Austria) on March 1, 2018.

The European consortium [Hypmed](#) will present a huge step forward in the project, dedicated to the development of an innovative medical imaging device, making more secure breast cancer diagnosis and follow-up – 1<sup>st</sup> reason of death by cancer for women.

### Intrasense recognized for its expertise

Through the project, Intrasense develops and industrialize very specific software applications, based on its platform, [Myrian® Imaging Layer](#) and Myrian® Studio, for the reading and analysis of PET/MRI images produced by the new device.

*« We are particularly proud to collaborate in this technological and clinical breakthrough project. », said Philippe Michelon, Product Director at Intrasense. « Intrasense has high expectations on market diffusion of this unique device, dramatically improving the quality of the patient chain of care. »*

### Hypmed: innovating for breast cancer diagnosis

Funded by European Commission up to 5.5 million, the Hypmed project aims to develop by 2019 device and software solutions, based on an innovative hybrid PET/MRI technology.

Techniques used increase the sensitivity and specificity of cancer detection for clinicians, earlier and more efficient for undetected cases. Less benign lesions will be detected at a secure level unseen, avoiding biopsies and unnecessary treatment, aggressive and costly. Moreover, the cost of this new device will be much less expensive, unlike PET/MRI current solutions on the market.

The Hypmed consortium is composed of German, Dutch and Austrian universities and 3 actors of medical imaging sector, like Intrasense or the Dutch manufacturer Philips. The clinical leadership is led by the teaching hospital of Aix-la-Chapelle (France), acting through Professor Christiane Khul, recognized worldwide for her work on breast cancer MRI imaging.



[HYPMED at ECR 2018](#) - European Congress of Radiology - Vienna (Austria)  
Thursday, March 1, 2018, 16:00-17:30; Austria Center, Room L8

### About Intrasense

Founded in 2004, Intrasense develops and markets a unique medical device called Myrian®, a software platform that facilitates diagnosis, decision-making and therapeutic follow-up and makes them more secure. Thanks to Myrian®, more than 800 health institutions spread over 40 countries use a unique and integrated platform supporting all types of imaging modalities (MRI, scanner...). Enriched with expert clinical modules dedicated to specific pathologies, Myrian® also provides a universal image treatment solution that can be fully integrated in any health information system. Intrasense includes 45 employees among which 20 are dedicated to Research & Development. Intrasense has been labelled 'innovative company' by the BPI and invested more than 10 million euros in Research & Development since its creation.

Further information, visit [www.intrasense.fr](http://www.intrasense.fr).

### Contacts

Intrasense  
Nicolas Reymond  
Chief Executive Officer  
Christophe Lamboeuf  
Chief Financial Officer  
Tel: +33 4 67 130 130  
[investor@intrasense.fr](mailto:investor@intrasense.fr)

NewCap  
Investor communication  
Valentine Brouchet  
Pierre Laurent

Tel: +33 1 44 71 94 96  
[intrasense@newcap.eu](mailto:intrasense@newcap.eu)

